161 related articles for article (PubMed ID: 9619864)
1. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
Sadzuka Y; Hirotsu S; Hirota S
Cancer Lett; 1998 May; 127(1-2):99-106. PubMed ID: 9619864
[TBL] [Abstract][Full Text] [Related]
2. Effective prodrug liposome and conversion to active metabolite.
Sadzuka Y
Curr Drug Metab; 2000 Jul; 1(1):31-48. PubMed ID: 11467079
[TBL] [Abstract][Full Text] [Related]
3. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
Sadzuka Y; Hirotsu S; Hirota S
Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894
[TBL] [Abstract][Full Text] [Related]
4. Liposomalization of SN-38 as active metabolite of CPT-11.
Sadzuka Y; Takabe H; Sonobe T
J Control Release; 2005 Nov; 108(2-3):453-9. PubMed ID: 16182400
[TBL] [Abstract][Full Text] [Related]
5. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
[TBL] [Abstract][Full Text] [Related]
6. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
8. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
Iwase Y; Maitani Y
Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
[TBL] [Abstract][Full Text] [Related]
9. Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity.
Zhang Z; Yao J
AAPS PharmSciTech; 2012 Sep; 13(3):802-10. PubMed ID: 22639238
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats.
Atsumi R; Okazaki O; Hakusui H
Biol Pharm Bull; 1995 Aug; 18(8):1114-9. PubMed ID: 8535406
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
14. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
[TBL] [Abstract][Full Text] [Related]
15. A Stable Irinotecan Liposome with Enhanced Antitumor Activity in a Range of Tumor Models.
Su Z; Li L; Hao F; Zhao J; Li M; Zhao X; Zhao D
Pharm Res; 2023 Dec; 40(12):3043-3058. PubMed ID: 37914843
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
17. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11.
Takeda S; Shimazoe T; Kuga H; Sato K; Kono A
Biochem Biophys Res Commun; 1992 Oct; 188(1):70-7. PubMed ID: 1329748
[TBL] [Abstract][Full Text] [Related]
18. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Prijovich ZM; Chen KC; Roffler SR
Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model.
Atsumi R; Okazaki O; Hakusui H
Biol Pharm Bull; 1995 Jul; 18(7):1024-6. PubMed ID: 7581244
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
